Cere­vance's $47M raise; Parex­el's AI pact

Plus, news about In­tra-Cel­lu­lar:

Cere­vance adds $47 mil­lion to Se­ries B: The neu­ro­log­i­cal dis­ease biotech’s se­ries B-1 raise now sits at $98 mil­lion, with in­vest­ments from Agent Cap­i­tal, Bi­o­lu­mi­nes­cence Ven­tures, and Dou­ble Point Ven­tures, among oth­ers. The com­pa­ny’s ini­tial se­ries B closed in 2020, but it raised $51 mil­lion in ear­ly 2023 as part of the B-1 raise. Cere­vance said it plans to use the mon­ey to­wards its pipeline pro­grams, in­clud­ing start­ing a Phase 3 clin­i­cal tri­al for a Parkin­son’s dis­ease drug. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER